Merck KGaA tops MediciNova on 8 of 15 metrics

Merck KGaA led MediciNova on 8 of 15 comparative stock factors in a Bbns trade-press article published Oct. 11, citing MarketBeat data on profitability, ownership, risk, valuation and analyst ratings.

The Oct. 11 article reported Merck KGaA gross revenue of $23.87 billion, versus $410,000 for MediciNova, without specifying the reporting period. It also cited net income of $2.95 billion for Merck KGaA, compared with a $12 million loss for MediciNova.

The contrast is stark because the two healthcare companies sit at very different stages and scales. Merck KGaA, based in Darmstadt, Germany, operates across life science, healthcare and electronics, while MediciNova is a La Jolla, California-based biopharmaceutical developer focused on small-molecule therapies.

On risk, the article said MediciNova had a beta of 0.61, meaning its shares were 39% less volatile than the S&P 500. Merck KGaA’s beta was listed at 0.95, or 5% less volatile than the index.

Profitability also favored Merck KGaA in the cited data. The company had an 11.20% net margin, 8.10% return on equity and 4.58% return on assets. MediciNova’s figures were negative: a net margin of minus 1,168.70%, return on equity of minus 26.51% and return on assets of minus 24.39%.

Analyst ratings favored MediciNova in the article’s summary. MarketBeat data showed one sell rating, one hold rating, four buy ratings and one strong-buy rating for MediciNova, producing a rating score of 2.71. Merck KGaA had six hold ratings and a score of 2.00.

The article said MediciNova had a consensus price target of $7.75, implying 409.87% potential upside. That target is an analyst consensus cited by MarketBeat, not a forecast by Atlas360.

Ownership data were mixed. The article said institutions held 9.9% of MediciNova shares and 0.1% of Merck KGaA shares, while insiders held 14.0% of MediciNova.

The comparison did not provide current share prices, trading times, market capitalization, the dates of the analyst ratings or the reporting periods behind the revenue and earnings figures.

Source: trade-press article, Bbns, Oct. 11, 2026